局部晚期宫颈癌患者血清KRT17蛋白表达水平对动脉介入新辅助化疗效果的影响

doi:10.3969/j.issn.1004-616x.2024.02.005

癌变·畸变·突变 ›› 2024, Vol. 36 ›› Issue (2): 112-117.doi: 10.3969/j.issn.1004-616x.2024.02.005

• 论著 • 上一篇

局部晚期宫颈癌患者血清KRT17蛋白表达水平对动脉介入新辅助化疗效果的影响

张晓峰, 宋芳, 朱林忠

首都医科大学附属北京妇产医院放射科, 北京100006

收稿日期:2023-06-20 修回日期:2023-10-16 发布日期:2024-04-11
通讯作者: 朱林忠
作者简介:张晓峰,E-mail: zhangxiaofeng_73@163.com。
基金资助:
北京市科技计划课题(Z171100000417027)

Expression levels of the serum KRT17 protein in patients with locally advanced cervical cancer and its impact on response to neoadjuvant chemotherapy

ZHANG Xiaofeng, SONG Fang, ZHU Linzhong

Radiology Department of Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University, Beijing 100006, China

Received:2023-06-20 Revised:2023-10-16 Published:2024-04-11

摘要/Abstract

摘要： 目的：检测局部晚期宫颈癌(LACC)患者血清角蛋白 17(KRT17)的表达水平，及其对动脉介入新辅助化疗(NACT)效果的影响。方法：选取2017年1月—2018年6月就诊的70例LACC患者，采用动脉介入新辅助化疗联合手术治疗，治疗前通过酶联免疫吸附试验(ELISA)检测患者血清KRT17蛋白的浓度，根据其中位数水平，分为低表达组及高表达组，比较两组患者的无进展生存期(PFS)、总生存期(OS)、盆腔无进展生存期(PPFS)、无远处转移生存期(DMFS)的差异，以评价KRT17蛋白在采用新辅助化疗的LACC患者中的表达水平及其临床意义。结果：LACC患者血清KRT17蛋白浓度中位数为0.65 μg/L，所有患者的KRT17蛋白浓度范围为0.49~1.26 μg/L。34例患者为低表达组，36例患者为高表达组。血清KRT17蛋白浓度用于预测LACC患者的NACT疗效的受试者工作特征(ROC)曲线下面积(AUC)为0.897[95%CI(0.816，0.978)]，敏感性和特异性分别为90.6%、81.6%。血清KRT17低表达组和高表达组患者中位 PFS分别为 57.23和 48.75个月；中位 OS分别为 58.1和 55.5个月；中位 PPFS分别为 56.9和 49.9个月；中位 DMFS分别为57.1和50.1个月。Kaplan-Meier生存曲线显示血清KRT17表达水平升高与LACC患者PFS、OS、PPFS、DMFS缩短呈现正相关(P<0.01)。结论：KRT17蛋白在LACC患者血清中表达升高，且其升高水平可作为NACT治疗LACC患者预后不良的预测因素。

关键词: 角蛋白17, 局部晚期宫颈癌, 新辅助化疗, 动脉介入化疗, 疗效

Abstract: OBJECTIVE： To determine expression levels of the serum keratin 17 (KRT17) protein in patients with locally advanced cervical cancer (LACC) and its impact on response to neoadjuvant chemotherapy (NACT). METHODS： From January 2017 to June 2018， 70 cervical cancer patients who visited our hospitalwere selected and they were treated with arterial interventional neoadjuvant chemotherapy combined with surgery. Before treatment， their serum KRT17 protein expression levels were measured by enzyme-linked immunosorbent assay (ELISA). According to the median level，they were divided into low expression and high expression groups. The progression free survival (PFS)， total survival (OS)， pelvic progression free survival (PPFS)，and pelvic progression free survival (PPFS) of the two groups of patients were compared to evaluate changes in the expression levels and in clinical significance with chemotherapy. There was a difference in distant metastasis free survival (DMFS). RESULTS： The median serum KRT17 level in LACC patients was 0.65 μg/L，and the range was 0.49-1.26 μg/L. There were 33 patients in the low expression group and 36 in the high expression group. The area under the subject operating characteristic (ROC) curve (AUC) of serum KRT17 for predicting the efficacy of NACT in the patients was 0.897 [95%CI (0.816，0.978)]，with sensitivity and specificity of 90.6% and 81.6%，respectively. The median PFS of patients with low and high expression of serum KRT17 was 57.23 and 48.75 months， respectively； The median OS was 58.1 and 55.5 months， respectively； The median PPFS was 56.9 and 49.9 months， respectively； The median DMFS was 57.1 and 50.1 months， respectively. The Kaplan Meier survival curve shows a positive correlation between increased serum KRT17 expression and shortened PFS， OS， PPFS， and DMFS in LACC patients. CONCLUSION： Expression of KRT17 protein in the serum of LACC patients was elevated，and the elevated levels can be a useful predictor for poor prognosis in LACC patients who were treated with NACT.

Key words: keratin 17, locally advanced cervical cancer, neoadjuvant chemotherapy, arterial interventional chemotherapy, curative effect

中图分类号:

R730.5

张晓峰, 宋芳, 朱林忠. 局部晚期宫颈癌患者血清KRT17蛋白表达水平对动脉介入新辅助化疗效果的影响[J]. 癌变·畸变·突变, 2024, 36(2): 112-117.

ZHANG Xiaofeng, SONG Fang, ZHU Linzhong. Expression levels of the serum KRT17 protein in patients with locally advanced cervical cancer and its impact on response to neoadjuvant chemotherapy[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 112-117.

参考文献

[1] BEDELL S L, GOLDSTEIN L S, GOLDSTEIN A R, et al. Cervical cancer screening:past, present, and future[J]. Sex Med Rev, 2020, 8(1):28-37.
[2] 中国抗癌协会妇科肿瘤专业委员会.子宫颈癌诊断与治疗指南(2021年版)[J].中国癌症杂志, 2021, 31(6):474-489.
[3] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[4] MIRIYALA R, MAHANTSHETTY U, MAHESHWARI A, et al. Neoadjuvant chemotherapy followed by surgery in cervical cancer:past, present and future[J]. Int J Gynecol Cancer, 2022, 32(3):260-265.
[5] GUPTA S, MAHESHWARI A, PARAB P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer:a randomized controlled trial[J]. J Clin Oncol, 2018, 36(16):1548-1555.
[6] DE AZEVEDO C R, THULER L C, DE MELLO M J, et al. Neoadjuvant chemotherapy followed by chemoradiation in cervical carcinoma:a review[J]. Int J Gynecol Cancer, 2016, 26(4):729-736.
[7] ROBOVA H, HALASKA M, PLUTA M, et al. The role of neoadjuvant chemotherapy and surgery in cervical cancer[J]. Int J Gynecol Cancer, 2010, 20(11 Suppl 2):S42-S46.
[8] LI Z G, CHEN J H, ZHAO S B, et al. Discovery and validation of novel biomarkers for detection of cervical cancer[J]. Cancer Med, 2021, 10(6):2063-2074.
[9] YANG L T, ZHANG S L, WANG G. Keratin 17 in disease pathogenesis:from cancer to dermatoses[J]. J Pathol, 2019, 247(2):158-165.
[10] ZHANG H Q, ZHANG Y, XIA T T, et al. The role of Keratin17 in human tumours[J]. Front Cell Dev Biol, 2022, 10:818416.
[11] HOBBS R P, BATAZZI A S, HAN M C, et al. Loss of Keratin 17 induces tissue-specific cytokine polarization and cellular differentiation in HPV16-driven cervical tumorigenesis in vivo[J]. Oncogene, 2016, 35(43):5653-5662.
[12] UJIIE D, OKAYAMA H, KONO K. The role of KRT17 in colorectal cancer[J]. Aging, 2021, 13(16):19950-19951.
[13] LI S, HU T, LV W G, et al. Changes in prevalence and clinical characteristics of cervical cancer in the People's Republic of China:a study of 10, 012 cases from a nationwide working group[J]. Oncologist, 2013, 18(10):1101-1107.
[14] SUN H Z, XIN J, LU Z M, et al. Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopical radical hysterectomy for patients with cervical cancer[J]. Cell Physiol Biochem, 2013, 32(5):1528-1540.
[15] NEOADJUVANT CHEMOTHERAPY FOR CERVICAL CANCER META-ANALYSIS COLLABORATION (NACCCMA) COLLABORATION. Neoadjuvant chemotherapy for locally advanced cervix cancer[J]. Cochrane Database Syst Rev, 2004, 2004(2):CD001774.
[16] MARTINEZ A, POILBLANC M, FERRON G, et al. Fertility-preserving surgical procedures, techniques[J]. Best Pract Res Clin Obstet Gynaecol, 2012, 26(3):407-424.
[17] NISHIO H, FUJII T, KAMEYAMA K, et al. Abdominal radical trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer in a series of 61 women[J]. Gynecol Oncol, 2009, 115(1):51-55.
[18] DARGENT D, MARTIN X, SACCHETONI A, et al. Laparoscopic vaginal radical trachelectomy:a treatment to preserve the fertility of cervical carcinoma patients[J]. Cancer, 2000, 88(8):1877-1882.
[19] BEINER M E, COVENS A. Surgery insight:radical vaginal trachelectomy as a method of fertility preservation for cervical cancer[J]. Nat Clin Pract Oncol, 2007, 4(6):353-361.
[20] KORENAGA T K, TEWARI K S. Gynecologic cancer in pregnancy[J]. Gynecol Oncol, 2020, 157(3):799-809.
[21] ZHANG Y, YU M H, JING Y, et al. Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer[J]. Br J Cancer, 2021, 124(2):414-424.

局部晚期宫颈癌患者血清KRT17蛋白表达水平对动脉介入新辅助化疗效果的影响

Expression levels of the serum KRT17 protein in patients with locally advanced cervical cancer and its impact on response to neoadjuvant chemotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价

[1]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[2]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[3]	焦文静, 郭秀娟, 马鸣, 邵俊国, 张金艳. 老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较[J]. 癌变·畸变·突变, 2021, 33(2): 124-128.
[4]	刘晓霞, 李卫霞, 苏镇军, 贾金海, 段晓辉, 李志加, 贺晓磊, 吕林林, 刘睿, 王云晓. 晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系[J]. 癌变·畸变·突变, 2020, 32(5): 350-354.
[5]	阿衣古丽·哈热, 陆艳荣, 伊斯刊达·阿不力米提, 张瑾熔. 直肠癌新辅助放化疗前后LGR5基因表达的变化及其与疗效的关系[J]. 癌变·畸变·突变, 2017, 29(1): 60-64,69.
[6]	程云杰,王雅棣*,刘青,张钧,万欣. MnSOD基因单核苷酸多态性对食管癌局部放疗的影响[J]. , 2011, 23(1): 9-012.